These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9988543)

  • 21. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
    Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
    J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
    Arpino G; Green SJ; Allred DC; Lew D; Martino S; Osborne CK; Elledge RM
    Clin Cancer Res; 2004 Sep; 10(17):5670-6. PubMed ID: 15355892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
    Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.
    De Laurentiis M; Arpino G; Massarelli E; Ruggiero A; Carlomagno C; Ciardiello F; Tortora G; D'Agostino D; Caputo F; Cancello G; Montagna E; Malorni L; Zinno L; Lauria R; Bianco AR; De Placido S
    Clin Cancer Res; 2005 Jul; 11(13):4741-8. PubMed ID: 16000569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT; Robert NJ
    Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response.
    Rydén L; Stendahl M; Jonsson H; Emdin S; Bengtsson NO; Landberg G
    Breast Cancer Res Treat; 2005 Jan; 89(2):135-43. PubMed ID: 15692755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
    J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.
    Lipton A; Leitzel K; Ali SM; Demers L; Harvey HA; Chaudri-Ross HA; Evans D; Lang R; Hackl W; Hamer P; Carney W
    Cancer; 2005 Jul; 104(2):257-63. PubMed ID: 15952182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial.
    Alkner S; Bendahl PO; Fernö M; Nordenskjöld B; Rydén L;
    Eur J Cancer; 2009 Sep; 45(14):2496-502. PubMed ID: 19535242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct likelihood inference and sensitivity analysis for competing risks regression with missing causes of failure.
    Moreno-Betancur M; Rey G; Latouche A
    Biometrics; 2015 Jun; 71(2):498-507. PubMed ID: 25761785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tests for homogeneity of the risk difference when data are sparse.
    Lipsitz SR; Dear KB; Laird NM; Molenberghs G
    Biometrics; 1998 Mar; 54(1):148-60. PubMed ID: 9544513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Number needed to treat for time-to-event data with competing risks.
    Gouskova NA; Kundu S; Imrey PB; Fine JP
    Stat Med; 2014 Jan; 33(2):181-92. PubMed ID: 24038032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Case-control methods in the presence of multiple failure times and competing risks.
    Lubin JH
    Biometrics; 1985 Mar; 41(1):49-54. PubMed ID: 4005386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of conditional and unconditional randomization tests for highly stratified designs.
    Flyer PA
    Biometrics; 1998 Dec; 54(4):1551-9. PubMed ID: 9883551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamic treatment allocation adjusting for prognostic factors for more than two treatments.
    Dror S; Faraggi D; Reiser B
    Biometrics; 1995 Dec; 51(4):1338-43. PubMed ID: 8589225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.